| Nov 15 |
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024
|
| Nov 14 |
Altimmune Third Quarter 2024 Earnings: Beats Expectations
|
| Nov 13 |
Altimmune: Pemvidutide As MASH Drug Could Provide Competitive Edge
|
| Nov 13 |
Altimmune's Pemvidutide Gains Momentum: Sizeable TAMs In Obesity And Liver Health
|
| Nov 12 |
Altimmune stock rallies 30% on business updates, UBS buy rating
|
| Nov 12 |
Altimmune, Inc. (ALT) Q3 2024 Earnings Call Transcript
|
| Nov 12 |
Altimmune beats Q3 estimates
|
| Nov 12 |
Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business Update
|
| Nov 12 |
Earnings Scheduled For November 12, 2024
|
| Nov 11 |
Altimmune Q3 2024 Earnings Preview
|
